Selected research
Industry Research
Sugammadex Industry Research Report 2026
Market perspective
The global Sugammadex market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Sugammadex is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Sugammadex is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Sugammadex is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Sugammadex include Renfu Pharma, Yangzi River Pharma, Teva, Sandoz, Merck & Co, Kelun Pharma, Viatris, STADA Arzneimittel and Intas Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Sugammadex market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Sugammadex Market by Company
Renfu Pharma
Yangzi River Pharma
Teva
Sandoz
Merck & Co
Kelun Pharma
Viatris
STADA Arzneimittel
Intas Pharmaceuticals
Hikma Pharmaceuticals
Fresenius
Dr Reddy's Laboratories
Cipla
Aspen Group
Sugammadex Segment by Type
Vials
Ampoules
Sugammadex Segment by Application
Hospital
Mobile Surgery Centre
Sugammadex Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sugammadex market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sugammadex and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sugammadex.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Sugammadex manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Sugammadex by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Sugammadex in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vials
- Ampoules
Applications
- Hospital
- Mobile Surgery Centre
Companies covered
- Renfu Pharma
- Yangzi River Pharma
- Teva
- Sandoz
- Merck & Co
- Kelun Pharma
- Viatris
- STADA Arzneimittel
- Intas Pharmaceuticals
- Hikma Pharmaceuticals
- Fresenius
- Dr Reddy's Laboratories
- Cipla
- Aspen Group
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Sugammadex Market Size (2021-2032)
- 2.2.2 Global Sugammadex Sales (2021-2032)
- 2.2.3 Global Sugammadex Market Average Price (2021-2032)
- 2.3 Sugammadex by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Vials
- 2.3.3 Ampoules
- 2.4 Sugammadex by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Mobile Surgery Centre
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Sugammadex Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Sugammadex Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Sugammadex Revenue of Manufacturers (2021-2026)
- 3.4 Global Sugammadex Average Price by Manufacturers (2021-2026)
- 3.5 Global Sugammadex Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Sugammadex, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Sugammadex, Product Type & Application
- 3.8 Global Manufacturers of Sugammadex, Established Date
- 3.9 Global Sugammadex Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Renfu Pharma
- 4.1.1 Renfu Pharma Company Information
- 4.1.2 Renfu Pharma Business Overview
- 4.1.3 Renfu Pharma Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Renfu Pharma Sugammadex Product Portfolio
- 4.1.5 Renfu Pharma Recent Developments
- 4.2 Yangzi River Pharma
- 4.2.1 Yangzi River Pharma Company Information
- 4.2.2 Yangzi River Pharma Business Overview
- 4.2.3 Yangzi River Pharma Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Yangzi River Pharma Sugammadex Product Portfolio
- 4.2.5 Yangzi River Pharma Recent Developments
- 4.3 Teva
- 4.3.1 Teva Company Information
- 4.3.2 Teva Business Overview
- 4.3.3 Teva Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Teva Sugammadex Product Portfolio
- 4.3.5 Teva Recent Developments
- 4.4 Sandoz
- 4.4.1 Sandoz Company Information
- 4.4.2 Sandoz Business Overview
- 4.4.3 Sandoz Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sandoz Sugammadex Product Portfolio
- 4.4.5 Sandoz Recent Developments
- 4.5 Merck & Co
- 4.5.1 Merck & Co Company Information
- 4.5.2 Merck & Co Business Overview
- 4.5.3 Merck & Co Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck & Co Sugammadex Product Portfolio
- 4.5.5 Merck & Co Recent Developments
- 4.6 Kelun Pharma
- 4.6.1 Kelun Pharma Company Information
- 4.6.2 Kelun Pharma Business Overview
- 4.6.3 Kelun Pharma Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Kelun Pharma Sugammadex Product Portfolio
- 4.6.5 Kelun Pharma Recent Developments
- 4.7 Viatris
- 4.7.1 Viatris Company Information
- 4.7.2 Viatris Business Overview
- 4.7.3 Viatris Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Viatris Sugammadex Product Portfolio
- 4.7.5 Viatris Recent Developments
- 4.8 STADA Arzneimittel
- 4.8.1 STADA Arzneimittel Company Information
- 4.8.2 STADA Arzneimittel Business Overview
- 4.8.3 STADA Arzneimittel Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 STADA Arzneimittel Sugammadex Product Portfolio
- 4.8.5 STADA Arzneimittel Recent Developments
- 4.9 Intas Pharmaceuticals
- 4.9.1 Intas Pharmaceuticals Company Information
- 4.9.2 Intas Pharmaceuticals Business Overview
- 4.9.3 Intas Pharmaceuticals Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Intas Pharmaceuticals Sugammadex Product Portfolio
- 4.9.5 Intas Pharmaceuticals Recent Developments
- 4.10 Hikma Pharmaceuticals
- 4.10.1 Hikma Pharmaceuticals Company Information
- 4.10.2 Hikma Pharmaceuticals Business Overview
- 4.10.3 Hikma Pharmaceuticals Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hikma Pharmaceuticals Sugammadex Product Portfolio
- 4.10.5 Hikma Pharmaceuticals Recent Developments
- 4.11 Fresenius
- 4.11.1 Fresenius Company Information
- 4.11.2 Fresenius Business Overview
- 4.11.3 Fresenius Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Fresenius Sugammadex Product Portfolio
- 4.11.5 Fresenius Recent Developments
- 4.12 Dr Reddy's Laboratories
- 4.12.1 Dr Reddy's Laboratories Company Information
- 4.12.2 Dr Reddy's Laboratories Business Overview
- 4.12.3 Dr Reddy's Laboratories Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Dr Reddy's Laboratories Sugammadex Product Portfolio
- 4.12.5 Dr Reddy's Laboratories Recent Developments
- 4.13 Cipla
- 4.13.1 Cipla Company Information
- 4.13.2 Cipla Business Overview
- 4.13.3 Cipla Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Cipla Sugammadex Product Portfolio
- 4.13.5 Cipla Recent Developments
- 4.14 Aspen Group
- 4.14.1 Aspen Group Company Information
- 4.14.2 Aspen Group Business Overview
- 4.14.3 Aspen Group Sugammadex Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Aspen Group Sugammadex Product Portfolio
- 4.14.5 Aspen Group Recent Developments
5 Global Sugammadex Market Scenario by Region
- 5.1 Global Sugammadex Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Sugammadex Sales by Region: 2021-2032
- 5.2.1 Global Sugammadex Sales by Region: 2021-2026
- 5.2.2 Global Sugammadex Sales by Region: 2027-2032
- 5.3 Global Sugammadex Revenue by Region: 2021-2032
- 5.3.1 Global Sugammadex Revenue by Region: 2021-2026
- 5.3.2 Global Sugammadex Revenue by Region: 2027-2032
- 5.4 North America Sugammadex Market Facts & Figures by Country
- 5.4.1 North America Sugammadex Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Sugammadex Sales by Country (2021-2032)
- 5.4.3 North America Sugammadex Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Sugammadex Market Facts & Figures by Country
- 5.5.1 Europe Sugammadex Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Sugammadex Sales by Country (2021-2032)
- 5.5.3 Europe Sugammadex Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Sugammadex Market Facts & Figures by Country
- 5.6.1 Asia Pacific Sugammadex Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Sugammadex Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Sugammadex Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Sugammadex Market Facts & Figures by Country
- 5.7.1 South America Sugammadex Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Sugammadex Sales by Country (2021-2032)
- 5.7.3 South America Sugammadex Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Sugammadex Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Sugammadex Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Sugammadex Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Sugammadex Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Sugammadex Sales by Type (2021-2032)
- 6.1.1 Global Sugammadex Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Sugammadex Sales Market Share by Type (2021-2032)
- 6.2 Global Sugammadex Revenue by Type (2021-2032)
- 6.2.1 Global Sugammadex Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Sugammadex Revenue Market Share by Type (2021-2032)
- 6.3 Global Sugammadex Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Sugammadex Sales by Application (2021-2032)
- 7.1.1 Global Sugammadex Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Sugammadex Sales Market Share by Application (2021-2032)
- 7.2 Global Sugammadex Revenue by Application (2021-2032)
- 7.2.1 Global Sugammadex Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Sugammadex Revenue Market Share by Application (2021-2032)
- 7.3 Global Sugammadex Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Sugammadex Value Chain Analysis
- 8.1.1 Sugammadex Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Sugammadex Production Mode & Process
- 8.2 Sugammadex Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Sugammadex Distributors
- 8.2.3 Sugammadex Customers
9 Global Sugammadex Analyzing Market Dynamics
- 9.1 Sugammadex Industry Trends
- 9.2 Sugammadex Industry Drivers
- 9.3 Sugammadex Industry Opportunities and Challenges
- 9.4 Sugammadex Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst